Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

The Egyptian pharmaceutical market is considered one ... By buying two successful local manufacturing facilities with their generic brands, GSK has better market access than companies which ...

"Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients" was originally created and published by ...

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.